598 related articles for article (PubMed ID: 29167971)
1. Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial.
Bilezikian JP; Hattersley G; Fitzpatrick LA; Harris AG; Shevroja E; Banks K; Leder BZ; Zanchetta JR; Hans D
Osteoporos Int; 2018 Feb; 29(2):323-328. PubMed ID: 29167971
[TBL] [Abstract][Full Text] [Related]
2. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
[TBL] [Abstract][Full Text] [Related]
3. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
[TBL] [Abstract][Full Text] [Related]
4. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
McClung MR; Lippuner K; Brandi ML; Zanchetta JR; Bone HG; Chapurlat R; Hans D; Wang A; Zapalowski C; Libanati C
Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study.
Senn C; Günther B; Popp AW; Perrelet R; Hans D; Lippuner K
Osteoporos Int; 2014 Jul; 25(7):1945-51. PubMed ID: 24760244
[TBL] [Abstract][Full Text] [Related]
6. Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtend.
Cosman F; Hans D; Shevroja E; Wang Y; Mitlak B
J Bone Miner Res; 2023 Apr; 38(4):464-470. PubMed ID: 36588166
[TBL] [Abstract][Full Text] [Related]
7. Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis.
Watts NB; Hattersley G; Fitzpatrick LA; Wang Y; Williams GC; Miller PD; Cosman F
Osteoporos Int; 2019 Jun; 30(6):1187-1194. PubMed ID: 30899994
[TBL] [Abstract][Full Text] [Related]
8. Effects of Teriparatide and Sequential Minodronate on Lumbar Spine Bone Mineral Density and Microarchitecture in Osteoporosis.
Miyaoka D; Imanishi Y; Ohara M; Hayashi N; Nagata Y; Yamada S; Mori K; Emoto M; Inaba M
Calcif Tissue Int; 2017 Oct; 101(4):396-403. PubMed ID: 28589205
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
[TBL] [Abstract][Full Text] [Related]
10. Effects of Teriparatide, Denosumab, or Both on Spine Trabecular Microarchitecture in DATA-Switch: a Randomized Controlled Trial.
Tsai JN; Jiang LA; Lee H; Hans D; Leder BZ
J Clin Densitom; 2017; 20(4):507-512. PubMed ID: 28624340
[TBL] [Abstract][Full Text] [Related]
11. Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture.
Saag KG; Williams SA; Wang Y; Weiss RJ; Cauley JA
Clin Ther; 2020 Jun; 42(6):1099-1107.e1. PubMed ID: 32513495
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effect of rhPTH(1-84) on Bone Mineral Density and Trabecular Bone Score in Hypoparathyroidism and Postmenopausal Osteoporosis.
Cipriani C; Pepe J; Silva BC; Rubin MR; Cusano NE; McMahon DJ; Nieddu L; Angelozzi M; Biamonte F; Diacinti D; Hans D; Minisola S; Bilezikian JP
J Bone Miner Res; 2018 Dec; 33(12):2132-2139. PubMed ID: 30088838
[TBL] [Abstract][Full Text] [Related]
13. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE.
Eastell R; Mitlak BH; Wang Y; Hu M; Fitzpatrick LA; Black DM
Osteoporos Int; 2019 Mar; 30(3):667-673. PubMed ID: 30635696
[TBL] [Abstract][Full Text] [Related]
14. Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis.
McClung MR; Harvey NC; Fitzpatrick LA; Miller PD; Hattersley G; Wang Y; Cosman F
Menopause; 2018 Jul; 25(7):767-771. PubMed ID: 29462094
[TBL] [Abstract][Full Text] [Related]
15. Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density.
Miller PD; Troy S; Weiss RJ; Annett M; Schense J; Williams SA; Mitlak B
Clin Drug Investig; 2021 Mar; 41(3):277-285. PubMed ID: 33638863
[TBL] [Abstract][Full Text] [Related]
16. Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats.
Bahar H; Gallacher K; Downall J; Nelson CA; Shomali M; Hattersley G
Calcif Tissue Int; 2016 Nov; 99(5):489-499. PubMed ID: 27395059
[TBL] [Abstract][Full Text] [Related]
17. Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.
Cosman F; Miller PD; Williams GC; Hattersley G; Hu MY; Valter I; Fitzpatrick LA; Riis BJ; Christiansen C; Bilezikian JP; Black D
Mayo Clin Proc; 2017 Feb; 92(2):200-210. PubMed ID: 28160873
[TBL] [Abstract][Full Text] [Related]
18. Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors.
Cosman F; Hattersley G; Hu MY; Williams GC; Fitzpatrick LA; Black DM
J Bone Miner Res; 2017 Jan; 32(1):17-23. PubMed ID: 27612281
[TBL] [Abstract][Full Text] [Related]
19. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
20. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability.
McCloskey EV; Fitzpatrick LA; Hu MY; Williams G; Kanis JA
Arch Osteoporos; 2019 Feb; 14(1):15. PubMed ID: 30719589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
